AJOVista LLC Buys New Position in MaxCyte, Inc. (NASDAQ:MXCT)

AJOVista LLC acquired a new stake in MaxCyte, Inc. (NASDAQ:MXCT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,000 shares of the company’s stock, valued at approximately $70,000.

Other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. acquired a new stake in MaxCyte during the 3rd quarter worth approximately $31,000. Johnson Investment Counsel Inc. acquired a new stake in shares of MaxCyte in the third quarter valued at $34,000. Aigen Investment Management LP purchased a new position in MaxCyte in the third quarter valued at $44,000. Nisa Investment Advisors LLC grew its stake in MaxCyte by 47,100.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock worth $55,000 after purchasing an additional 11,775 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in MaxCyte by 350.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $56,000 after purchasing an additional 9,323 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Price Performance

MXCT stock traded down $0.06 during trading on Friday, hitting $3.77. 477,877 shares of the company’s stock were exchanged, compared to its average volume of 451,874. The business has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $4.34. MaxCyte, Inc. has a 52-week low of $2.45 and a 52-week high of $5.55.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $15.60 million. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. Equities research analysts anticipate that MaxCyte, Inc. will post -0.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on MXCT. William Blair reiterated an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th. BTIG Research lowered their price target on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. Finally, Stephens restated an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a report on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.